Notice of Decision for Xalkori - Health Canada

Health Canada has issued a Notice of Compliance under the Notice of Compliance with Conditions (NOC/c) Guidance to Pfizer Canada Inc. for the drug product Xalkori. Xalkori is indicated as monotherapy for use in patients with ALK-positive advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC). Read more here.